2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 210.042 | 182.850 | 295.010 | 295.651 | 295.166 | 286.517 | 280.234 | 252.296 | 232.835 | 212.297 |
Total Income - EUR | 239.553 | 189.891 | 298.733 | 299.827 | 297.236 | 288.399 | 283.185 | 255.480 | 233.138 | 218.941 |
Total Expenses - EUR | 211.957 | 189.421 | 281.341 | 287.465 | 284.839 | 285.471 | 268.337 | 234.238 | 216.880 | 202.993 |
Gross Profit/Loss - EUR | 27.596 | 470 | 17.392 | 12.362 | 12.396 | 2.928 | 14.848 | 21.242 | 16.258 | 15.948 |
Net Profit/Loss - EUR | 22.928 | 152 | 13.721 | 7.872 | 9.428 | 44 | 12.203 | 18.917 | 14.230 | 13.802 |
Employees | 5 | 4 | 5 | 5 | 5 | 6 | 6 | 5 | 4 | 4 |
Check the financial reports for the company - Viofarm S.r.l.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 29.610 | 27.649 | 26.451 | 26.027 | 26.232 | 24.528 | 24.171 | 21.636 | 19.881 | 18.554 |
Current Assets | 201.507 | 201.093 | 142.960 | 142.360 | 138.635 | 149.596 | 149.393 | 155.319 | 168.672 | 127.955 |
Inventories | 30.889 | 30.792 | 32.141 | 30.116 | 18.958 | 23.211 | 20.991 | 21.351 | 30.672 | 28.492 |
Receivables | 167.154 | 166.518 | 101.895 | 108.706 | 109.117 | 103.679 | 98.655 | 97.910 | 95.248 | 92.906 |
Cash | 3.464 | 3.783 | 8.924 | 3.538 | 10.560 | 22.705 | 29.747 | 36.059 | 42.752 | 6.557 |
Shareholders Funds | 141.457 | 142.789 | 112.241 | 118.108 | 120.845 | 114.112 | 120.017 | 136.273 | 150.926 | 83.405 |
Social Capital | 896 | 903 | 894 | 879 | 863 | 846 | 830 | 811 | 814 | 811 |
Debts | 89.660 | 90.540 | 57.171 | 50.279 | 44.023 | 61.522 | 53.546 | 40.682 | 37.628 | 63.104 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4773 - 4773" | |||||||||
CAEN Financial Year |
4773
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Viofarm S.r.l.